Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Recent Quotes
My Watchlist
Indicators
FATE THERAPEUTIC RG (NQ: FATE)
12.84 USD  -0.24 (-1.83%)
Official Closing Price  /  Updated: 8:00 PM EDT, Jun 22, 2018  /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 2,277,928
Open 13.08
Bid (Size) 12.21 (4800)
Ask (Size) 14.00 (500)
Prev. Close 13.08
Today's Range 12.48 - 13.14
52wk Range 2.520 - 14.45
Shares Outstanding 52,858,446
Dividend Yield N/A
Performance
YTD
+103.81%
+103.81%
1 Month
+13.93%
+13.93%
3 Month
+17.58%
+17.58%
6 Month
+128.88%
+128.88%
1 Year
+302.51%
+302.51%
Top News
More News
Mixed close as Trump targets drug costs
The markets closed mixed with the Dow climbing 91 points to 24,831 as President Donald Trump vowed to lower drug costs. Nasdaq eased 2 points to 7402. Read More
category Market News
from MarketMinute.com Market Updates
Fate Therapeutics to Present at the Jefferies 2018 Global Healthcare Conference
Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today... Read More
from GlobeNewswire News Releases
More News
Read More
Analysis: Positioning to Benefit within Beazer Homes, Tejon Ranch, Ladder Capital, Fate Therapeutics, Benefitfocus, and H&E Equipment Services — Research Highlights Growth, Revenue, and Consolidated R
from GlobeNewswire News Releases
Fate Therapeutics and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies
from GlobeNewswire News Releases
Fate Therapeutics Reports First Quarter 2018 Financial Results and Highlights Operational Progress
from GlobeNewswire News Releases
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2018 Financial Results
from GlobeNewswire News Releases
Fate Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
from GlobeNewswire News Releases
Implied PTH Analyst Target Price: $102
category ETFs
from ETF Channel
5 Stocks Moving In Thursday's After-Hours Session
category FSCT , Trading Ideas , JNCE , and 8 more.
from Benzinga
Short Interest Expands By 25.4% For FATE
category Stocks
from Market News Video
10 Stocks To Watch For May 7, 2018
category SNCR , Markets , TSN , and 17 more.
from Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Six Financial & Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.